Abstract
Previous findings indicated that schizophrenia (SZ) patients have increased breakdown of membrane phospholipids. The present study is thus to test whether the resulting plasma FFAs are altered at early course of disease development, and if so, whether such changes can be affected by treatment of atypical antipsychotic drugs (AAPD).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
